Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05270434
Other study ID # Optimal Timing of Endoscopic
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date March 1, 2022
Est. completion date February 1, 2023

Study information

Verified date February 2022
Source Changhai Hospital
Contact Zhuan Liao
Phone 13061921980
Email liaozhuan@smmu.edu.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study aims to determine the optimal timing of endoscopic intervention after extracorporeal shock wave lithotripsy(ESWL) of chronic pancreatitis with pancreatic stones.


Description:

Chronic pancreatitis(CP)is a chronic progressive fibro-inflammatory disease of the pancreas induced by a wide range of factors including genetic and environmental elements, with recurrent abdominal pain and pancreatic secretion insufficiency as its major clinical signs. Chronic pancreatitis is not only a tough disease of the gastrointestinal system but also a worldwide medical problem. At present, the MESS (medicine-extracorporeal shock wave lithotripsy-endoscopic retrograde cholangiopancreatography-surgery)formed by changhai hospital in CP diagnosis and treatment is gradually becoming mature, and the clinical effect of this system is obvious. However, there are still some difficulties and knowledge gaps in the clinical treatment of CP. Currently, it is recommended by both domestic and foreign guidelines that ERCP combined with ESWL as the first-line treatment pattern for patients with chronic pancreatitis associate pain. It has previously been observed that ERCP performed less than 2 days after ESWL may be more likely to fail, possibly owing to ESWL-induced edema. However, there is no high-quality research to demonstrate how to choose the most optimal timing of ERCP after ESWL for patients with indications for endoscopic treatment. This prospective, randomized controlled research has therefore aimed to determine the most optimal timing of ERCP after ESWL. Patients with painful chronic pancreatitis and pancreatic stones larger than 5 mm in diameter will be randomly and equally assigned to three groups, which are divided according to the time interval between ESWL and ERCP, including <12 hours subgroup, 12~36 hours subgroup and >36 hours subgroup. The cannulation success rate and stone clearance rate of the pancreatic duct will be assessed in each group to explore the most appropriate timing of ERCP, and then provide an important reference basis for the clinical treatment of chronic pancreatitis.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 225
Est. completion date February 1, 2023
Est. primary completion date January 3, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. symptomatic adult patients diagnosed with chronic pancreatitis and main pancreatic duct positive stones(>5mm in diameter) 2. no ERCP and ESWL history before the admission 3. provides informed consent Exclusion Criteria: 1. suspected to have malignant tumors; 2. history of pancreatic surgery or gastrojejunostomy (Billroth II); 3. with end-stage disease; 4. with contraindications to ESWL or ERCP, such as pregnancy, abdominal aortic aneurysm, etc. 5. acute pancreatitis within 3 days 6. pancreatic ascites

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
time interval between ESWL and ERCP is 12h
The patients received intravenous analgesia before the ESWL. After the last ESWL session, the patients are treated with following ERCP within 12h.
time interval between ESWL and ERCP is 12-36h
The patients received intravenous analgesia before the ESWL. After the last ESWL session, the patients are treated with following ERCP within 12-36h.
time interval between ESWL and ERCP is greater than 36h
The patients received intravenous analgesia before the ESWL. After the last ESWL session, the patients are treated with following ERCP >36h.
Drug:
morphine, buprenorphine, pethidine, tramaldol, metamizole and acetylsalicylacid (Analgesics)
Analgesics administrated include morphine, buprenorphine, pethidine, tramaldol, metamizole and acetylsalicylacid. They will only be administrated as needed.

Locations

Country Name City State
China Changhai Hospital Shanghai

Sponsors (1)

Lead Sponsor Collaborator
Changhai Hospital

Country where clinical trial is conducted

China, 

References & Publications (1)

Guo JY, Qian YY, Sun H, Chen H, Zou WB, Hu LH, Li ZS, Xin L, Liao Z. Optimal Timing of Endoscopic Intervention After Extracorporeal Shock-Wave Lithotripsy in the Treatment of Chronic Calcified Pancreatitis. Pancreas. 2021 Apr 1;50(4):633-638. doi: 10.1097/MPA.0000000000001810. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Treatment-related costs in RMB from initial enrollment to the end of the study The total costs in RMB of each hospitalization through endotherapy completion, an average of 14days
Other The hospitalization time Length of hospitalization due to ESWL /ERCP and complications through endotherapy completion, an average of 14days
Primary Successful MPD Cannulation Rates technical success rate of pancreatic cannulation during ERCP procedure
Secondary Successful clearance of MPD stones Ductal clearance has been defined as complete, partial, or unsuccessful if the proportion of stones cleared was > 90 %, 50 %-90 %, or < 50 %, respectively. during ERCP procedure
Secondary post-ERCP complications Major post-ERCP complications includes post-ERCP pancreatitis, bleeding, infection, and perforation, which are classified as mild, moderate, or severe, depending mainly on the length of hospitalization and the need for invasive treatment. 30 days
Secondary severity of post-ERCP complications severity are classified as mild, moderate, or severe, depending mainly on the length of hospitalization and the need for invasive treatment. 30 days
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05326542 - Comparison of Efficacy of ESWL and Laser Lithotripsy in Chronic Pancreatitis With ERCP N/A
Completed NCT01731821 - Nonstented Stump-closed vs Duct-to-Mucosa Pancreaticojejunostomy After Pancreaticoduodenectomy Phase 3
Completed NCT01551511 - Δ9-THC (Namisol®) in Chronic Pancreatitis Patients Suffering From Persistent Abdominal Pain Phase 2
Active, not recruiting NCT05095831 - EUS Shear Wave for Solid Pancreatic Lesions.
Completed NCT03173118 - Elastography in the Diagnosis of Chronic Pancreatitis N/A
Terminated NCT01318590 - Prospective Study on Endoscopic Ultrasound (EUS) Celiac Bloc Efficacy in Chronic Pancreatitis Phase 3
Recruiting NCT05772234 - Aggressive Intravenous Hydration With Lactated Ringer's Solution for Prevention of Post-ESWL Pancreatitis N/A
Recruiting NCT04131010 - Digital Catheter Based Pancreatoscopy (SpyGlassDS) for the Management of Symptomatic Pancreatic Duct Stones in Selected Patients With Chronic Pancreatitis N/A
Terminated NCT00359320 - A Randomized Trial of Two Surgical Techniques for Pancreaticojejunostomy in Patients Undergoing Pancreaticoduodenectomy N/A
Completed NCT02940067 - Enhancing Fitness Before Pancreatic Surgery N/A
Recruiting NCT05261997 - Endotherapy for Painless Chronic Pancreatitis N/A
Completed NCT03672422 - Pediatric Longitudinal Cohort Study of Chronic Pancreatitis
Enrolling by invitation NCT05287737 - Clinical Outcome After Total Pancreatectomy With Islet Autotransplantation
Not yet recruiting NCT06426160 - Tocilizumab for Painful Chronic Pancreatitis Phase 2
Enrolling by invitation NCT05289362 - Comparison of Efficacy of Basket and Balloon in the Removal of Pancreatic Duct Stones in Chronic Pancreatitis Under ERCP N/A
Not yet recruiting NCT04760847 - Intermittent Fasting for Pancreatitis N/A
Enrolling by invitation NCT03228095 - Volatiles in Breath and Headspace Analysis - Diagnostic Markers
Completed NCT00956839 - Prospective Study of Efficacy of Intra-muscular Vitamin D3 in Tropical Calcific Pancreatitis Phase 4
Completed NCT00676702 - A Study of the Enzyme Activity and Safety of Pancrelipase in Patients With Severe Exocrine Pancreatic Insufficiency (EPI) Phase 1
Recruiting NCT04672642 - Evaluation of the SpyGlass DS for Detection of Residual Pancreatic Calculations N/A